Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 26172
Label UNT Clip pédagogique

le (13m5s)

Tableau de bord stratégique / Balanced Scorecard

Le Balanced scorecard (BSC), traduit par tableau de bord stratégique (ou prospectif ou équilibré) est un modèle de tableau de bord permettant de piloter la performance en s'appuyant sur la stratégie de l'entreprise et les facteurs clés de succès de l'activité. Moins financiers et de court terme que ses prédécesseurs, le BSC repose sur la recherche de la valeur pour les actionnaires et les clients à travers 4 perspectives dont les indicateurs (de résultats et d'actions) sont reliés par des relations de causalité (axes Financier, Clients, Processus internes et Apprentissage organisationnel). Il s'agit d'identifier les indicateurs qui assurent la dynamique ...
Voir la vidéo
Conférences

le (18m51s)

On the authority of the qadi’s judgement: the mufti of Amid and the genealogies ofOttoman Hanafism

La justice dans la société ottomane, Institutions, acteurs et pratiques (16ème- 20ème siècles)6-7 janvier 2012, Institut Français d’études Anatoliennes - IstanbulSession: Quand différents corps de droit (chéria, kanun et coutume) et systèmes juridiques se croisent (9h30-12h45)Yavuz Aykan (doctorant EHESS/Université de Munich) : “On the authority of the qadi’s judgement: the mufti of Amid and the genealogies ofOttoman Hanafism.”
Voir la vidéo
Conférences

le (13m2s)

BRIO's facts and figures, structuration projects : Axe Cancer, translational research centerUpdate the implementation of BRIO

Update the implementation of BRIO Brio organisation is now fully up and running, and more than 100 research projects are currently active into the 6 integrated research programmes. In addition, major progresses were achieved at the level of the 7 strategic axes defined to structure and support cancer research in Bordeaux. The bioinformatics axis saw the recruitment of 4 bioinformaticians (2 funded by BRIO) and the creation of a transversal bioinformatics axis at the University. For the in-vivo research axis, a project to develop a translational research center is currently being developed ...
Voir la vidéo
Conférences

le (18m29s)

Sociology contribution to understanding the (no)diffusion of a medical innovation

Interface technology/clinical/SHS/public health : case study interventional radiology We will present results of an undergoing study on the socioeconomic processes of recognition in oncology of a long-standing medical innovation, the so-called interventional radiology (IR). This project is conducted by a multidisciplinary team gathering health sociologist, sociologist of science, economist of innovation, health lawyer and interventional radiologist, supported by INCa. With scientometrics and patent landscaping, we get an understanding of the IR discoveries’ chronology and identify the relationships established between science, medicine and industry. Through field observations and semi-directed interviews, we analyzed the strategies of legitimation of IR, seeking ...
Voir la vidéo
Conférences

le (19m21s)

Cost-effectiveness analysis for decision making, illustrated theory

Interface technology/clinical/SHS/public health : case study interventional radiologyIn a health care system with limited resources, each euro invested in a health care intervention is no longer available for another intervention. This imposes the need for a prioritization of health care interventions according to their additional value for money for maximizing health at a given cost. Cost-effectiveness analyses may answer two main questions: 1) does an intervention present sufficient value for money to be funded within a health system? The decision is based on the absolute value of the incremental cost-effectiveness ratio; 2) is further research needed to inform the decision ...
Voir la vidéo
Conférences

le (9m11s)

Innovation reimbursement

Interface technology/clinical/SHS/public health : case study interventional radiology Novel diagnostic and therapeutic strategies is a continuum of 3 strongly associated phases : clinical research, medico-economic evaluation of a novel strategy and deployment of innovation, the last one being a field of competence of centers of expertise such as SIRIC BRIO.In the full cycle of innovation, the money time is the major challenge of a large deployment. The main problem is to find money. But, in 2015, 3 changes should improve the innovation continuum. Should it be a progress, an obstacle, or both ?...Cette présentation a été donnée dans ...
Voir la vidéo
Conférences

le (13m9s)

Multisarc

Translational science : how to move from biology to clinical applications Soft-tissues sarcomas represent an heterogeneous group of tumors. Stadard of care is surgical resection followed by radiotherapy. Patients with metastatic relapse are treated with chemotherapy but the overall survival is only approximatly 18 months. Actual research try to define new therapeutic targets, adapted to the type of sarcoma. The personalized medicine project aims to propose to patients with advanced sarcoma a targeted therapy based on the genomic and immunilogical profile. The main difference with other projects resides in ...
Voir la vidéo
Conférences

le (18m24s)

A new preclinical model to test the response of breast cancer to genomically targeted therapy

Translational science : how to move from biology to clinical applicationsThe rapid progress in next generation DNA sequencing technology (NGS) means it is now possible, in principle, to obtain a complete list of the genetic abnormalities in a tumour. In practice, clinicians use NGS to obtain a much shorter list of "actionable" mutations that can be targeted with available drugs or used as prognostic markers. Unfortunately, the mere presence of an actionable mutation does not guarantee a response to the cognate drug, as shown by the SAFIR1 study (André et al 2014). To spare patients unnecessary exposure to experimental drugs, ...
Voir la vidéo
Conférences

le (16m55s)

Bordeaux Cancer Initiative

Translational science : how to move from biology to clinical applicationsUpon request of the University, the SIRIC was mandated to develop a transversal cancer axis at the University. The axis development was led by BRIO management team along with a committee representing various disciplines within the University having an interest for cancer research. The axis definition focused on cancer research complementary to the SIRIC BRIO and is based mostly on basic and technological research. Five programmes are part of the axis: interaction radiation/living beings, nanotechnologies and innovations, tumor microenvironment, risk and predictions, cell remodelling. 150 scientists from 27 Bordeaux institutes ...
Voir la vidéo

 
FMSH
 
Facebook Twitter
Mon Compte